Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Coherus Oncology (Nasdaq: CHRS) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, followed by a management conference call and webcast starting at 5:00 p.m. Eastern Daylight Time.

Rhea-AI Summary

Coherus Oncology (Nasdaq: CHRS) will release its second quarter 2026 financial results on Wednesday, August 5, 2026, followed by a management conference call and webcast starting at 5:00 p.m. Eastern Daylight Time. Investors can pre-register online to receive dial-in details and a personal PIN, or access the live and archived webcast via the Coherus investors website.

According to Coherus Oncology, the company uses its investors website for disclosure of material information under Regulation FD. The release also highlights LOQTORZI, an approved PD-1 inhibitor, and mid-stage pipeline candidates tagmokitug and casdozokitug in various solid tumor indications.

Argus Jul 22 session

-2.72% close to close Open Argus

Details

News Market Reaction – CHRS

In the Jul 22 session, CHRS declined 2.72%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Comparable earnings-date announcements averaged -2.54% across two tagged events. That record adds ca...

Analysis

Comparable earnings-date announcements averaged -2.54% across two tagged events. That record adds caution to this scheduling notice; the active S-3 is not effective, and the August release remains the key information point.

Key Figures

Reporting period: Q2 2026 Release date: August 5, 2026 Conference call time: 5:00 p.m. Eastern Daylight Time +3 more

Reporting period

Q2 2026

Financial results scheduled for release

Release date

August 5, 2026

Second-quarter financial results

Conference call time

5:00 p.m. Eastern Daylight Time

August 5, 2026

Tagmokitug study phase

Phase 1b/2a

Advanced solid tumors

Casdozokitug study phase

Phase 2

First-line hepatocellular carcinoma

Pipeline candidates

two

Mid-stage clinical candidates

Previous Earnings date Reports

2 past events · Latest: May 04

Same Type 2 events

1. May 04

   Q1 earnings date

   24h Move

   -3.9%

   Scheduled first-quarter results release and management conference call announcement

2. Mar 02

   FY2025 earnings date

   24h Move

   -1.2%

   Scheduled full-year and fourth-quarter results release and webcast announcement

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pd-1 inhibitor, phase 1b/2a, anti-ccr8 antibody, regulation fd

4 terms

pd-1 inhibitor medical

"with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor"

A PD-1 inhibitor is a type of medicine that helps the immune system recognize and attack cancer cells by blocking the PD-1 checkpoint—a molecular “off switch” that cancer can use to hide from immune defenses. For investors, these drugs matter because they can transform treatment options, drive sales or partnerships, and affect a company’s valuation if clinical trials, approvals, or competitive positioning change; think of them as unlocking a locked door to let the body’s defenses work.

phase 1b/2a medical

"currently in Phase 1b/2a studies in patients with advanced solid tumors"

Phase 1b/2a is a combined early-stage clinical study that first tests safety and optimal dosing in a small group and then expands to look for initial signs that the drug works in the target patients. Think of it as a prototype test followed by a small pilot run: it helps companies decide whether to invest in larger, more expensive trials. Investors watch these results because they reduce scientific uncertainty and can sharply affect a drug’s value and development timeline.

anti-ccr8 antibody medical

"a highly selective cytolytic anti-CCR8 antibody"

An anti-CCR8 antibody is a laboratory-made protein designed to bind to CCR8, a receptor found on certain immune cells, and alter their behavior. For investors, these drugs matter because they represent a targeted approach in drug development—like a key designed for a specific lock—that can change clinical trial results, development timelines, regulatory outcomes, and potential market value for companies working on immune-related diseases or cancer therapies.

regulation fd regulatory

"for complying with its disclosure obligations under Regulation FD"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m. Eastern Daylight Time on August 5, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Wednesday, August 5, 2026, starting at 5:00 p.m. Eastern Daylight Time.

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BId137c93eda7d4cf0b60be1df98d9b99f

Webcast: https://edge.media-server.com/mmc/p/vhd7ef6h

The press release with the second quarter 2026 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Please dial in 15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI^® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI^® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:

Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Coherus Oncology (CHRS) report its Q2 2026 financial results?

Coherus Oncology will report its Q2 2026 financial results on Wednesday, August 5, 2026. According to Coherus Oncology, a conference call and webcast to discuss the results and provide a business update will start at 5:00 p.m. Eastern Daylight Time that day.

How can investors access the Coherus Oncology (CHRS) Q2 2026 earnings call?

Investors can access the Coherus Oncology Q2 2026 earnings call by pre-registering via the provided online link to receive dial-in details and a personal PIN. According to Coherus Oncology, a live and archived webcast will also be available on the company’s Investors website.

Where will the Coherus Oncology (CHRS) Q2 2026 earnings press release be available?

The Coherus Oncology Q2 2026 earnings press release and related materials will be available at https://investors.coherus.com before the call. According to Coherus Oncology, this investors website is also used to disclose material non-public information under Regulation FD for shareholders.

What is LOQTORZI in the Coherus Oncology (CHRS) product portfolio?

LOQTORZI is an approved next-generation PD-1 inhibitor in the Coherus Oncology portfolio. According to Coherus Oncology, the company’s strategy is to grow LOQTORZI sales in recurrent or metastatic nasopharyngeal carcinoma and develop combination regimens with pipeline candidates for multiple cancer types.

Which clinical candidates are in Coherus Oncology’s (CHRS) pipeline as of July 2026?

Coherus Oncology’s pipeline includes tagmokitug, a cytolytic anti-CCR8 antibody in Phase 1b/2a, and casdozokitug, an IL-27 antagonist in Phase 2. According to Coherus Oncology, these candidates target advanced solid tumors and first-line hepatocellular carcinoma in combination strategies with LOQTORZI.

How does Coherus Oncology (CHRS) plan to grow its oncology business?

Coherus Oncology aims to grow by increasing LOQTORZI sales in R/M nasopharyngeal carcinoma and advancing two mid-stage pipeline candidates. According to Coherus Oncology, the company focuses on antibody immunotherapies enhancing innate and adaptive immune responses across several solid tumor indications.